20 results about "Immune serums" patented technology

The invention discloses a conservative B cell epitope peptide of goose parvovirus VP3 protein, a nucleic acid molecule, a recombinant vector and application thereof. Conservative B cell epitope EW12 is inserted into F18 Escherichia coli Fod fimbriae, inert carrier bacteria S9H are introduced, recombinant bacteria capable of functionally exhibiting and expressing the EW12 conservative B cell epitope on the surface of the bacteria are obtained, the recombinant bacteria can specifically generate specific binding reaction with gosling plague egg yolk antibody and gosling plague vaccine immune serum, and the gosling plague egg yolk antibody and the gosling plague vaccine immune serum can be specifically combined with the gosling plague egg yolk antibody and the gosling plague vaccine immune serum. The method has the advantages that macroscopic agglutination particles are generated, cross agglutination reaction with other pathogen positive serum and healthy goose serum is avoided, the method is good in sensitivity, and the specific antibody can be detected in the 5th day after immunization at the earliest. A plate agglutination test directly mediated by the goose parvovirus VP3 protein conservative B cell epitope peptide EW12 has the advantages of specificity, sensitivity, convenience in operation and suitability for on-site large-scale rapid detection, and is expected to provide a new technical means for diagnosis, prevention and control and purification of GPV infection.

The invention belongs to the technical field of molecular biology, and discloses a truncated outer membrane protein of klebsiella pneumoniae and application thereof. The invention provides an outer membrane protein Lol B of klebsiella pneumoniae, which can be used for immunizing to induce a protective antibody aiming at various serotypes of klebsiella pneumoniae and killing the klebsiella pneumoniae. Specifically, the outer membrane protein Lol B immune serum can efficiently kill Klebsiella pneumoniae, and when a mouse immunized by the outer membrane protein Lol B immune serum is attacked by K1, K2 and K6 serotype Klebsiella pneumoniae, the mouse can be completely protected to survive, and the trend of weight loss of the mouse is remarkably reduced. Therefore, the outer membrane protein Lol B provided by the invention has a clinical application value for preventing and treating klebsiella pneumoniae infection.

A general formula for lysins based on which the activity and functionality are further screened and 24 lysins are identified and further investigated, nine of which are characterized. These lysins exhibit potent bactericidal activity, capable of lysing multiple species of Staphylococcus, Streptococcus, and / or Enterococcus; demonstrate robust environmental resistance and stability, retaining activity under varying temperatures, NaCl concentrations, pH levels, and in immune serum; and effectively treat localized and systemic infections. These lysins and their variants are promising as antimicrobial agents for eradicating bacteria, preventing bacterial infections, or treating bacterial infections (caused by genera Staphylococcus, Streptococcus, and / or Enterococcus).

The application discloses a kind of areca alkaloid artificial hapten, artificial antigen and its preparation method and application, with norarecoline hydrochloride as the starting material for synthesizing artificial hapten.This areca alkaloid artificial hapten retains the characteristic structure of areca alkaloid to the greatest extent, and has active groups that can couple with carrier proteins, which can be used as antigenic determinants;Further, the areca alkaloid artificial antigen obtained can be used to immunize to obtain an anti-areca alkaloid artificial antibody with high affinity, high sensitivity and strong specificity.The titer of the immune serum obtained by immunizing New Zealand white rabbits is as high as 1:70000, and can be used for rapid and accurate immunodetection and immunoassay of areca alkaloid.

The invention discloses a polyclonal antibody of panda Rbp7 protein as well as a preparation method and application thereof, and belongs to the technical field of antibodies. The first to nineteenth amino acid sequences of the panda Rbp7 protein are used as antigen polypeptides, and are specifically shown as SEQ ID No.1. After chemical synthesis or exogenous expression purification, a Balb / C mouse is immunized, and the polyclonal antibody is obtained through repeated immunization, serum titer detection and affinity chromatography purification. The titer of the antibody is not lower than 1 / 128000, the panda Rbp7 recombinant protein can be efficiently and specifically detected through WB and ELISA, the blank of a protein detection tool is filled, and reliable technical support is provided for research on the functional mechanism of the panda Rbp7 protein.

The application discloses a method for improving the sensitivity of a porcine circovirus type 2 Cap protein antigen agar diffusion detection, and belongs to the technical field of veterinary products. The method is as follows: (1) inoculating piglets with a porcine circovirus 2a, 2b and 2d trivalent virus-like particle vaccine, and then separating serum to obtain a porcine circovirus 2a, 2b and 2d trivalent high-immune serum; (2) preparing a high-salt agar plate; (3) diluting the trivalent high-immune serum and the porcine circovirus type 2 Cap protein antigen with a high-salt diluent, respectively, and then adding the diluted trivalent high-immune serum and the porcine circovirus type 2 Cap protein antigen into holes of the agar plate, and incubating at 35-37 DEG C for 20-24 h to complete the detection. The application uses high-immune serum and an improved agar diffusion method to quantitatively detect the content of PCV2 Cap protein, and avoids the defects of low tolerance to buffer reagents and poor detection specificity of the commonly used BCA or Bradford protein content detection method.

The application discloses a colloidal gold test strip for distinguishing between wild toxin infection and vaccine immunization of porcine pleuropneumonia actinobacillus and application. The test strip of the application takes ApxIVA truncated protein with an amino acid sequence shown as SEQ ID NO. 3 as an antigen, the truncated protein can be soluble expressed in E. coli, and the structure and function of the truncated protein are close to those of natural apxIVA. The test strip of the application comprises a sample pad, a colloidal gold pad, an NC membrane, a water absorption filter paper and a bottom plate, the colloidal gold pad is coated with gold-labeled apxIVA truncated protein and gold-labeled chicken IgY antibody, and the C line and the T line of the NC membrane are fixed with goat anti-chicken IgY antibody and apxIVA truncated protein. The test strip only needs 25 muL of pig serum to make detection within 5-10 min, and can distinguish between APP wild strain infection and gene deletion vaccine APP-HB-04M immunized serum samples.

The utility model discloses a polyclonal antibody immune serum vacuum blood sampling device, and relates to the technical field of blood sampling instruments, the polyclonal antibody immune serum vacuum blood sampling device comprises a blood sampling tube, the upper end and the lower end of the blood sampling tube are not sealed, the upper end opening of the blood sampling tube is connected with an end cover in a clamping mode, the end cover comprises a cover shell, and the cover shell is provided with a sealing cover. A cover shell is arranged in the blood collection tube, a leather plug is embedded in the cover shell, the leather plug is made of an antibacterial elastic material, an airtight self-inspection piece is clamped to a lower end opening of the blood collection tube, the airtight self-inspection piece comprises a transparent sealing shell, and a transparent sealing plug is embedded in the transparent sealing shell. The vacuum degree in the blood collection tube is visually reflected through the elastic membrane cloth, when the elastic membrane cloth deforms, the guide rod and the indicator at the bottom of the guide rod are driven to move together, and the color indication mark is arranged on the indication strip, so that the blood collection tube is convenient to use. And the vacuum degree in the blood sampling tube can be checked by observing the color interval of the indicator on the indication strip.

The application belongs to the technical field of antibodies, and particularly relates to an antibody for specifically treating orf of milk goat kids and application thereof. Virus liquid of a diseased goat is collected from a lesion site, and ORFV virus strains are obtained through subculture and amplification of goat skin fibroblasts; milk goats are immunized with a weak vaccine to prepare high-titer immune serum; flow sorting technology is used to separate ORFV-specific B cells from PBMC (peripheral blood mononuclear cells); antibody genes are amplified through nested PCR, expression vectors are constructed, and 293T cells are transfected to express monoclonal antibodies. The monoclonal antibody No. 2 obtained in the application has high affinity and specificity, the heavy chain CDR1-3 region sequence is SEQ ID NO: 1-3, and the light chain CDR1-3 region sequence is SEQ ID NO: 4-6. The antibody can be used for diagnosis, treatment and prevention of orf of goats, and has the characteristics of high efficiency, specificity and stability, and provides a new biological preparation for prevention and control of orf of goats.

The invention discloses a monospecific monoclonal antibody for resisting zearalenone-14 glucoside and application of the monospecific monoclonal antibody. An immunogen and a coating antigen are used; the monoclonal antibody capable of monospecifically recognizing the zearalenone-14 glucoside and the rapid detection kit for detecting the zearalenone-14 glucoside are obtained through the technologies of mouse immunization, serum detection, cell fusion, monoclonal screening, ascites induced antibody and the like. The method is suitable for single-specificity trace residue detection of the zearalenone-14 glucoside in samples such as corn, rice, millet, wheat and oat, has very high recognition sensitivity to the zearalenone-14 glucoside, and realizes rapid, large-batch and low-cost detection of the zearalenone-14 glucoside.

The invention discloses a B cell epitope peptide based on human papilloma virus E6 protein and application of the B cell epitope peptide in cancer diagnosis. According to the invention, the epitope peptide is displayed and expressed on the surface of an inert carrier bacterium S9H, so that an RI5 epitope peptide-antibody direct mediated agglutination test detection system based on thallus surface epitope display is successfully constructed. Compared with an immunoserological detection technology based on a complete protein antigen, the kit provided by the invention can be used for more specifically, sensitively, conveniently and quickly detecting the virus oncoprotein specific antibody in the body of an HPV persistent infection patient, and can be used for qualitatively and quantitatively determining the content of the antibody. The epitope peptide-antibody direct mediation agglutination test detection technology provides an efficient and reliable new method for accurate diagnosis of dynamic changes of virus oncoprotein antibodies in persistent infection and cancer stages of HPV patients, and has potential important clinical application value.

The application discloses a blocking agent for milk allergen component-specific IgE antibody test strips and application, and belongs to the technical field of immune detection and analysis. The blocking agent uses soybean protein isolate and fish gelatin as the blocking agent in antigen-antibody reaction of immunoserological technology, so as to reduce false negative results caused by using conventional blocking agents, casein and bovine serum albumin, and thus makes the detection result more accurate.

The invention provides a rabbit polyclonal antibody aiming at primary cilia and a preparation method thereof, and belongs to the technical field of biology, and the preparation method comprises the following steps: taking a 200-428 amino acid sequence of human ARL13B protein as a target fragment, synthesizing a gene after codon optimization, cloning the gene to a pet-32a expression vector, and carrying out induced expression in escherichia coli to obtain the rabbit polyclonal antibody aiming at primary cilia. Purifying to obtain high-purity immunogen protein; the nucleotide sequence of the synthetic gene is as shown in SEQ ID NO.1, and the amino acid sequence of the high-purity immunogen protein is as shown in SEQ ID NO.2. Immunizing a New Zealand white rabbit with the high-purity immunogen protein to obtain immune serum; and purifying the immune serum to obtain the rabbit polyclonal antibody. The prepared rabbit polyclonal antibody has higher specificity and signal strength, the titer can reach 1: 64000 or above through ELISA detection, primary cilia can be marked more clearly in a paraffin section immunofluorescence experiment, background noise is remarkably reduced, and the reliability of an experiment result is improved.

The invention provides a nano antigen particle containing an influenza virus NA antigen, an influenza virus vaccine based on the nano antigen particle and application of the influenza virus vaccine. The nano antigen particle can induce an organism to generate a high-level NA specific antibody, and immune serum of the organism can effectively inhibit enzyme activity reaction of homotype NA protein, so that the nano antigen particle has the potential of being developed into influenza virus vaccines.

The invention belongs to the technical field of biochemical engineering, and particularly relates to a medetomidine artificial hapten, an artificial antigen as well as a preparation method and application of the medetomidine artificial hapten and the artificial antigen. The medetomidine artificial hapten maximally retains the characteristic structure of medetomidine, has an active group capable of being coupled with carrier protein, and can be used as an antigenic determinant; the medetomidine artificial antigen obtained by further preparation can be immunized to obtain an anti-medetomidine polyclonal antibody with high affinity, high sensitivity and strong specificity, the titer of immune serum obtained by immunizing a New Zealand white rabbit is as high as 1: 135000, and the medetomidine artificial antigen can be used for rapid and accurate immunodetection and immunoassay of medetomidine.

The application discloses a fentanyl artificial hapten, a fentanyl artificial antigen and a preparation method and application thereof. The fentanyl artificial hapten of the application retains the characteristic structure of fentanyl to the maximum extent, and has an active group which can be coupled with a carrier protein and can serve as an antigenic determinant; the fentanyl artificial antigen prepared further can be used for immunization to obtain an anti-fentanyl antibody with high affinity, high sensitivity and high specificity, and the titer of the immune serum obtained by immunizing a New Zealand white rabbit is as high as 1:85000. The antigen and antibody can be used for enzyme-linked immunoassay, immunochromatography and the like, have the characteristics of high sensitivity, high specificity, strong operability and the like, and can be used for screening and detection of fentanyl components in various complex samples.

The invention discloses a monospecific anti-thiamethoxam monoclonal antibody and application thereof, the monoclonal antibody capable of recognizing thiamethoxam in a monospecific manner and a rapid detection kit for detecting thiamethoxam are obtained by using an immunogen and a coating antigen through the technologies of mouse immunization, serum detection, cell fusion, monoclonal screening, ascites induced antibody and the like. The method is suitable for single-specificity trace residue detection of thiamethoxam in lake water, beef, pork, spinach, eggs and other samples, has very high recognition sensitivity to thiamethoxam, and realizes rapid, large-scale and low-cost detection of thiamethoxam.

This invention discloses a method for preparing Akabane virus vaccine based on BEI inactivation and its application. This invention optimizes the BEI inactivation process for the AKAV_FS202301 Akabane virus strain, ensuring complete virus inactivation while effectively preserving the viral antigen structure. The prepared inactivated vaccine can induce high titers of neutralizing antibodies in experimental animals; specifically, the neutralizing antibody titer in rabbit immune serum is 5. 6 The neutralizing antibody titer in mouse immune serum was 5. 5 The obtained immune serum significantly reduced the viral RNA copy number of AKAV, inhibited viral replication activity, and significantly reduced the proportion of AKAV-infected positive cells. In summary, the Akabane virus vaccine provided by this invention achieves highly efficient antigen retention and significantly enhanced immune response, possessing advantages such as strong immunogenicity and significant viral inhibition effect, and has promising application prospects.

The invention discloses a preparation method and application of an akabane virus vaccine based on BEI inactivation. The BEI inactivation process is optimized aiming at the AKAVFS202301 akabane virus strain, so that the virus antigen structure is effectively reserved while the complete inactivation of the virus is ensured; the prepared inactivated vaccine can induce an experimental animal to generate a high-titer neutralizing antibody, the titer of the neutralizing antibody of rabbit immune serum is 56, the titer of the neutralizing antibody of mouse immune serum is 55, and the obtained immune serum can significantly reduce the virus RNA copy number of AKAV, inhibit virus replication activity and significantly reduce the proportion of positive cells infected with AKAV. In conclusion, the akabane virus vaccine provided by the invention realizes efficient antigen retention and remarkably enhanced immune response, has the advantages of strong immunogenicity, remarkable virus inhibition effect and the like, and has a good application prospect.

This invention belongs to the field of veterinary biological products, and relates to an O-type foot-and-mouth disease virus strain containing the VP1 T193A mutation site, its construction method, and its application in vaccine antigen escape research. The present invention provides an O-type foot-and-mouth disease virus mutant strain, which mutates threonine at position 193 of the VP1 protein of the wild-type O-type foot-and-mouth disease virus strain to alanine. The amino acid sequence of the mutated VP1 protein is shown in SEQ ID NO:2. The mutant strain rVP1-T193A constructed in this invention has highly similar lesion time, viral titer, and growth curve to rWT, but the neutralizing antibody titer to immune serum is reduced by 4.26 times, corresponding to an r value of 0.23, which is less than 0.3, potentially causing immune escape. This mutation significantly reduces the virus's sensitivity to neutralizing antibodies and can be used to study viral immune escape mechanisms and optimize vaccine design.